文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

全反式维甲酸通过减少CD34+前体细胞增殖抑制髓系来源抑制细胞生成的新用途:脂多糖免疫抑制模型研究

Novel Use of All-Trans-Retinoic Acid in A Model of Lipopolysaccharide-Immunosuppression to Decrease the Generation of Myeloid-Derived Suppressor Cells by Reducing the Proliferation of CD34+ Precursor Cells.
PubMed 文献 · Shock · 2017-01-01
一句话结论小鼠脂多糖免疫抑制模型中,全反式维甲酸在体内外减少CD34+前体细胞增殖,降低脾脏髓系来源抑制细胞数量并恢复T淋巴细胞增殖。

该研究在小鼠脂多糖诱导的免疫抑制模型中探讨全反式维甲酸(ATRA)对髓系生成和髓系来源抑制细胞(MDSC)的影响。结果显示,ATRA体内和体外给药均可减少免疫抑制小鼠中增多的CD34+前体细胞数量。机制上未发现CD34+前体细胞凋亡或向成熟细胞分化改变,而是ATRA降低了前体细胞增殖,表现为CD34+细胞形成的集落形成单位大小和数量减少以及3H-胸腺嘧啶掺入减少。ATRA还减少免疫抑制小鼠脾脏MDSC数量,恢复T淋巴细胞增殖和脾脏组织学结构。作者认为ATRA可能作为辅助治疗增强免疫应答。

要点

  • 在脂多糖免疫抑制小鼠中,ATRA体内和体外给药均减少增多的CD34+前体细胞数量。
  • ATRA未改变CD34+前体细胞凋亡或向成熟细胞分化,而是降低其增殖(集落形成单位大小和数量减少、3H-胸腺嘧啶掺入减少)。
  • ATRA减少免疫抑制小鼠脾脏MDSC数量,恢复T淋巴细胞增殖和脾脏组织学结构。
  • 作者认为ATRA可能作为辅助治疗,增强脓毒症所致免疫抑制状态下的免疫应答。

适用人群与场景

  • 脂多糖诱导免疫抑制的小鼠模型

处置流程与药物剂量

  • ATRA体内和体外给药,具体剂量、途径、频次原文未写明。

研究设计与关键结果

  • 研究类型为动物实验(小鼠),样本量原文未报告。
  • ATRA体内和体外给药减少免疫抑制小鼠中增多的CD34+前体细胞数量。
  • ATRA未改变CD34+前体细胞凋亡或向成熟细胞分化。
  • ATRA降低CD34+前体细胞增殖:集落形成单位大小和数量减少,3H-胸腺嘧啶掺入减少。
  • ATRA减少免疫抑制小鼠脾脏MDSC数量,恢复T淋巴细胞增殖和脾脏组织学结构。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

All-trans-retinoic acid (ATRA) is a derivative of vitamin A with antiproliferative properties. Endotoxin shock and subsequent immunosuppression (IS) by lipopolysaccharide (LPS) stimulates myelopoiesis with expansion of myeloid-derived suppressor cells (MDSC). Since we have previously shown that ATRA reverses the IS state by decreasing functional MDSC, our aim was to investigate if ATRA was able to modulate MDSC generation by regulating myelopoiesis in murine hematopoietic organs. We found that ATRA administration in vivo and in vitro decreased the number of CD34+ precursor cells that were increased in IS mice. When we studied the cellular mechanisms involved, we did not find any differences in apoptosis of CD34+ precursors or in the differentiation of these cells to their mature counterparts. Surprisingly, ATRA decreased precursor proliferation, in vitro and in vivo, as assessed by a reduction in the size and number of colony forming units generated from CD34+ cells and by a decreased incorporation of H-thymidine. Moreover, ATRA administration to IS mice decreased the number of MDSC in the spleen, with a restoration of T lymphocyte proliferation and a restitution of the histological architecture. Our results indicate, for the first time, a new use of ATRA to abolish LPS-induced myelopoiesis, affecting the proliferation of precursor cells, and in consequence, decreasing MDSC generation, having a direct impact on the improvement of immune competence. Administration of ATRA could overcome the immunosuppressive state generated by sepsis that often leads to opportunistic life-threatening infections. Therefore, ATRA could be considered a complementary treatment to enhance immune responses.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Martire-Greco D, Rodriguez-Rodrigues N, Castillo LA, et al. Novel Use of All-Trans-Retinoic Acid in A Model of Lipopolysaccharide-Immunosuppression to Decrease the Generation of Myeloid-Derived Suppressor Cells by Reducing the Proliferation of CD34+ Precursor Cells. Shock. 2017. PMID: 27922552. doi:10.1097/SHK.0000000000000812

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。